Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 64

1.

Stromal Hyaluronan Accumulation is Associated with Low Tumor Grade and Nodal Metastases in Pancreatic Ductal Adenocarcinoma.

Larson BK, Guan M, Placencio V, Tuli R, Hendifar AE.

Hum Pathol. 2019 May 20. pii: S0046-8177(19)30089-9. doi: 10.1016/j.humpath.2019.05.004. [Epub ahead of print]

PMID:
31121193
2.

Treatment strategies and clinical outcomes of locally advanced pancreatic cancer patients treated at high-volume facilities and academic centers.

David JM, Kim S, Placencio-Hickok VR, Torosian A, Hendifar A, Tuli R.

Adv Radiat Oncol. 2018 Nov 9;4(2):302-313. doi: 10.1016/j.adro.2018.10.006. eCollection 2019 Apr-Jun.

3.

The gut microbiome and response to immune checkpoint inhibitors: preclinical and clinical strategies.

Gong J, Chehrazi-Raffle A, Placencio-Hickok V, Guan M, Hendifar A, Salgia R.

Clin Transl Med. 2019 Mar 18;8(1):9. doi: 10.1186/s40169-019-0225-x. Review.

4.

Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as Biomarkers.

Singhi AD, George B, Greenbowe JR, Chung J, Suh J, Maitra A, Klempner SJ, Hendifar A, Milind JM, Golan T, Brand RE, Zureikat AH, Roy S, Schrock AB, Miller VA, Ross JS, Ali SM, Bahary N.

Gastroenterology. 2019 Jun;156(8):2242-2253.e4. doi: 10.1053/j.gastro.2019.02.037. Epub 2019 Mar 2.

5.

Long-Term Outcomes after Elective versus Emergency Surgery for Small Bowel Neuroendocrine Tumors.

Manguso N, Gangi A, Nissen N, Harit A, Siegel E, Hendifar A, Amersi F.

Am Surg. 2018 Oct 1;84(10):1570-1574.

PMID:
30747671
6.

A phase 1 study of veliparib, a PARP-1/2 inhibitor, with gemcitabine and radiotherapy in locally advanced pancreatic cancer.

Tuli R, Shiao SL, Nissen N, Tighiouart M, Kim S, Osipov A, Bryant M, Ristow L, Placencio-Hickok VR, Hoffman D, Rokhsar S, Scher K, Klempner SJ, Noe P, Davis MJ, Wachsman A, Lo S, Jamil L, Sandler H, Piantadosi S, Hendifar A.

EBioMedicine. 2019 Feb;40:375-381. doi: 10.1016/j.ebiom.2018.12.060. Epub 2019 Jan 8.

7.

Pancreas Cancer-Associated Weight Loss.

Hendifar AE, Petzel MQB, Zimmers TA, Denlinger CS, Matrisian LM, Picozzi VJ, Rahib L; Precision Promise Consortium.

Oncologist. 2019 May;24(5):691-701. doi: 10.1634/theoncologist.2018-0266. Epub 2018 Dec 27.

PMID:
30591550
8.

Combination systemic therapies with immune checkpoint inhibitors in pancreatic cancer: overcoming resistance to single-agent checkpoint blockade.

Gong J, Hendifar A, Tuli R, Chuang J, Cho M, Chung V, Li D, Salgia R.

Clin Transl Med. 2018 Oct 8;7(1):32. doi: 10.1186/s40169-018-0210-9. Review.

9.

Cardiac Toxicity in a Patient Receiving Peptide Receptor Radionuclide Therapy.

Hendifar AE, Delpassand ES, Kittleson MM, Tuli R.

Pancreas. 2018 Sep;47(8):e55-e56. doi: 10.1097/MPA.0000000000001101. No abstract available.

PMID:
30113434
10.

Phase 1 dose-escalation study of momelotinib, a Janus kinase 1/2 inhibitor, combined with gemcitabine and nab-paclitaxel in patients with previously untreated metastatic pancreatic ductal adenocarcinoma.

Ng K, Hendifar A, Starodub A, Chaves J, Yang Y, Koh B, Barbie D, Hahn WC, Fuchs CS.

Invest New Drugs. 2019 Feb;37(1):159-165. doi: 10.1007/s10637-018-0650-5. Epub 2018 Jul 30.

11.

The Evolving Treatment Algorithm for Advanced Neuroendocrine Neoplasms: Diversity and Commonalities Across Tumor Types.

Hendifar AE, Dhall D, Strosberg JR.

Oncologist. 2019 Jan;24(1):54-61. doi: 10.1634/theoncologist.2018-0187. Epub 2018 Aug 13. Review.

PMID:
30104288
12.

Rucaparib Monotherapy in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation.

Shroff RT, Hendifar A, McWilliams RR, Geva R, Epelbaum R, Rolfe L, Goble S, Lin KK, Biankin AV, Giordano H, Vonderheide RH, Domchek SM.

JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.17.00316. Epub 2018 May 16.

13.

Utility of Endoscopic Ultrasound-Guided Biopsy for Next-Generation Sequencing of Pancreatic Exocrine Malignancies.

Larson BK, Tuli R, Jamil LH, Lo SK, Deng N, Hendifar AE.

Pancreas. 2018 Sep;47(8):990-995. doi: 10.1097/MPA.0000000000001117.

PMID:
30028448
14.

Molecular Profiling of Patients with Pancreatic Cancer: Initial Results from the Know Your Tumor Initiative.

Pishvaian MJ, Bender RJ, Halverson D, Rahib L, Hendifar AE, Mikhail S, Chung V, Picozzi VJ, Sohal D, Blais EM, Mason K, Lyons EE, Matrisian LM, Brody JR, Madhavan S, Petricoin EF 3rd.

Clin Cancer Res. 2018 Oct 15;24(20):5018-5027. doi: 10.1158/1078-0432.CCR-18-0531. Epub 2018 Jun 28.

PMID:
29954777
15.

Primary Visceral Merkel Cell Carcinoma: A Case Report and Review of the Literature.

Siref A, Hendifar A, Balzer B.

Am J Dermatopathol. 2018 Dec;40(12):927-929. doi: 10.1097/DAD.0000000000001194. Review.

PMID:
29894357
16.

Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With 177Lu-Dotatate in the Phase III NETTER-1 Trial.

Strosberg J, Wolin E, Chasen B, Kulke M, Bushnell D, Caplin M, Baum RP, Kunz P, Hobday T, Hendifar A, Oberg K, Sierra ML, Thevenet T, Margalet I, Ruszniewski P, Krenning E; NETTER-1 Study Group.

J Clin Oncol. 2018 Sep 1;36(25):2578-2584. doi: 10.1200/JCO.2018.78.5865. Epub 2018 Jun 7.

17.

Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination.

Gong J, Le TQ, Massarelli E, Hendifar AE, Tuli R.

J Immunother Cancer. 2018 Jun 4;6(1):46. doi: 10.1186/s40425-018-0361-7. Review.

18.

The use of Ki-67 labeling index to grade pulmonary well-differentiated neuroendocrine neoplasms: current best evidence.

Marchevsky AM, Hendifar A, Walts AE.

Mod Pathol. 2018 Oct;31(10):1523-1531. doi: 10.1038/s41379-018-0076-9. Epub 2018 May 25.

PMID:
29802361
19.

Aldoxorubicin: a tumor-targeted doxorubicin conjugate for relapsed or refractory soft tissue sarcomas.

Gong J, Yan J, Forscher C, Hendifar A.

Drug Des Devel Ther. 2018 Apr 6;12:777-786. doi: 10.2147/DDDT.S140638. eCollection 2018. Review.

20.

Cachexia, and not obesity, prior to pancreatic cancer diagnosis worsens survival and is negated by chemotherapy.

Hendifar AE, Chang JI, Huang BZ, Tuli R, Wu BU.

J Gastrointest Oncol. 2018 Feb;9(1):17-23. doi: 10.21037/jgo.2017.11.10.

21.

Prognostic Factors Associated with Outcomes in Small Bowel Neuroendocrine Tumors.

Manguso N, Johnson J, Harit A, Nissen N, Mirocha J, Hendifar A, Amersi F.

Am Surg. 2017 Oct 1;83(10):1174-1178.

PMID:
29391119
22.

Phase II Study of BEZ235 versus Everolimus in Patients with Mammalian Target of Rapamycin Inhibitor-Naïve Advanced Pancreatic Neuroendocrine Tumors.

Salazar R, Garcia-Carbonero R, Libutti SK, Hendifar AE, Custodio A, Guimbaud R, Lombard-Bohas C, Ricci S, Klümpen HJ, Capdevila J, Reed N, Walenkamp A, Grande E, Safina S, Meyer T, Kong O, Salomon H, Tavorath R, Yao JC.

Oncologist. 2018 Jul;23(7):766-e90. doi: 10.1634/theoncologist.2017-0144. Epub 2017 Dec 14.

23.

HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma.

Hingorani SR, Zheng L, Bullock AJ, Seery TE, Harris WP, Sigal DS, Braiteh F, Ritch PS, Zalupski MM, Bahary N, Oberstein PE, Wang-Gillam A, Wu W, Chondros D, Jiang P, Khelifa S, Pu J, Aldrich C, Hendifar AE.

J Clin Oncol. 2018 Feb 1;36(4):359-366. doi: 10.1200/JCO.2017.74.9564. Epub 2017 Dec 12.

PMID:
29232172
24.

The Clinicopathological Aspects of Primary Presacral Neuroendocrine Neoplasms: One Center Experience.

Yang G, Dhall D, Yu R, Tuli R, Amersi FF, Friedman ML, Nissen NN, Hendifar AE.

Pancreas. 2018 Jan;47(1):122-129. doi: 10.1097/MPA.0000000000000954.

PMID:
29215535
25.

A pilot study evaluating concordance between blood-based and patient-matched tumor molecular testing within pancreatic cancer patients participating in the Know Your Tumor (KYT) initiative.

Pishvaian MJ, Joseph Bender R, Matrisian LM, Rahib L, Hendifar A, Hoos WA, Mikhail S, Chung V, Picozzi V, Heartwell C, Mason K, Varieur K, Aberra M, Madhavan S, Petricoin E 3rd, Brody JR.

Oncotarget. 2016 Nov 8;8(48):83446-83456. doi: 10.18632/oncotarget.13225. eCollection 2017 Oct 13.

26.

Wearable activity monitors in oncology trials: Current use of an emerging technology.

Gresham G, Schrack J, Gresham LM, Shinde AM, Hendifar AE, Tuli R, Rimel BJ, Figlin R, Meinert CL, Piantadosi S.

Contemp Clin Trials. 2018 Jan;64:13-21. doi: 10.1016/j.cct.2017.11.002. Epub 2017 Nov 9. Review.

27.

Multifocality in Small Bowel Neuroendocrine Tumors.

Gangi A, Siegel E, Barmparas G, Lo S, Jamil LH, Hendifar A, Nissen NN, Wolin EM, Amersi F.

J Gastrointest Surg. 2018 Feb;22(2):303-309. doi: 10.1007/s11605-017-3586-8. Epub 2017 Nov 8.

PMID:
29119527
28.

Moving Beyond Conventional Clinical Trial End Points in Treatment-refractory Metastatic Colorectal Cancer: A Composite Quality-of-life and Symptom Control End Point.

Gong J, Wu D, Chuang J, Tuli R, Simard J, Hendifar A.

Clin Ther. 2017 Nov;39(11):2135-2145. doi: 10.1016/j.clinthera.2017.09.015. Epub 2017 Oct 25. Review.

PMID:
29079389
29.

The role of pre-operative imaging and double balloon enteroscopy in the surgical management of small bowel neuroendocrine tumors: Is it necessary?

Manguso N, Gangi A, Johnson J, Harit A, Nissen N, Jamil L, Lo S, Wachsman A, Hendifar A, Amersi F.

J Surg Oncol. 2018 Feb;117(2):207-212. doi: 10.1002/jso.24825. Epub 2017 Sep 20.

PMID:
28940412
30.

Redefining the Positive Margin in Pancreatic Cancer: Impact on Patterns of Failure, Long-Term Survival and Adjuvant Therapy.

Osipov A, Nissen N, Rutgers J, Dhall D, Naziri J, Chopra S, Li Q, Hendifar AE, Tuli R.

Ann Surg Oncol. 2017 Nov;24(12):3674-3682. doi: 10.1245/s10434-017-6076-z. Epub 2017 Sep 5.

PMID:
28871564
31.

Identification of Targetable ALK Rearrangements in Pancreatic Ductal Adenocarcinoma.

Singhi AD, Ali SM, Lacy J, Hendifar A, Nguyen K, Koo J, Chung JH, Greenbowe J, Ross JS, Nikiforova MN, Zeh HJ, Sarkaria IS, Dasyam A, Bahary N.

J Natl Compr Canc Netw. 2017 May;15(5):555-562.

PMID:
28476735
32.

Most of the Intended Management Changes After 68Ga-DOTATATE PET/CT Are Implemented.

Calais J, Czernin J, Eiber M, Fendler WP, Gartmann J, Heaney AP, Hendifar AE, Pisegna JR, Hecht JR, Wolin EM, Slavik R, Gupta P, Quon A, Schiepers C, Allen-Auerbach MS, Herrmann K.

J Nucl Med. 2017 Nov;58(11):1793-1796. doi: 10.2967/jnumed.117.192450. Epub 2017 May 4.

33.

Statins and pancreatic cancer.

Gong J, Sachdev E, Robbins LA, Lin E, Hendifar AE, Mita MM.

Oncol Lett. 2017 Mar;13(3):1035-1040. doi: 10.3892/ol.2017.5572. Epub 2017 Jan 4.

34.

Identifying prognostic intratumor heterogeneity using pre- and post-radiotherapy 18F-FDG PET images for pancreatic cancer patients.

Yue Y, Osipov A, Fraass B, Sandler H, Zhang X, Nissen N, Hendifar A, Tuli R.

J Gastrointest Oncol. 2017 Feb;8(1):127-138. doi: 10.21037/jgo.2016.12.04.

35.

Private Funding for Pancreatic Cancer Research: More Than a Chip Shot.

Hendifar AE, Davies L, Tuli R.

Gastroenterology. 2017 Apr;152(5):918-921.e2. doi: 10.1053/j.gastro.2017.02.034. Epub 2017 Mar 1. No abstract available.

PMID:
28259790
36.

Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors.

Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, Mittra E, Kunz PL, Kulke MH, Jacene H, Bushnell D, O'Dorisio TM, Baum RP, Kulkarni HR, Caplin M, Lebtahi R, Hobday T, Delpassand E, Van Cutsem E, Benson A, Srirajaskanthan R, Pavel M, Mora J, Berlin J, Grande E, Reed N, Seregni E, Öberg K, Lopera Sierra M, Santoro P, Thevenet T, Erion JL, Ruszniewski P, Kwekkeboom D, Krenning E; NETTER-1 Trial Investigators.

N Engl J Med. 2017 Jan 12;376(2):125-135. doi: 10.1056/NEJMoa1607427.

37.

A Clinicopathological Study of Malignant Insulinoma in a Contemporary Series.

Yu R, Nissen NN, Hendifar A, Tang L, Song YL, Chen YJ, Fan X.

Pancreas. 2017 Jan;46(1):48-56.

PMID:
27984486
38.

Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy: SWOG S1115 Study Randomized Clinical Trial.

Chung V, McDonough S, Philip PA, Cardin D, Wang-Gillam A, Hui L, Tejani MA, Seery TE, Dy IA, Al Baghdadi T, Hendifar AE, Doyle LA, Lowy AM, Guthrie KA, Blanke CD, Hochster HS.

JAMA Oncol. 2017 Apr 1;3(4):516-522. doi: 10.1001/jamaoncol.2016.5383.

39.

Neuroendocrine Tumors of the Lung: Current Challenges and Advances in the Diagnosis and Management of Well-Differentiated Disease.

Hendifar AE, Marchevsky AM, Tuli R.

J Thorac Oncol. 2017 Mar;12(3):425-436. doi: 10.1016/j.jtho.2016.11.2222. Epub 2016 Nov 24. Review.

40.

Cultured circulating tumor cells and their derived xenografts for personalized oncology.

Wang R, Chu GCY, Mrdenovic S, Annamalai AA, Hendifar AE, Nissen NN, Tomlinson JS, Lewis M, Palanisamy N, Tseng HR, Posadas EM, Freeman MR, Pandol SJ, Zhau HE, Chung LWK.

Asian J Urol. 2016 Oct;3(4):240-253. doi: 10.1016/j.ajur.2016.08.005. Epub 2016 Aug 25. Review.

41.

Targeting mTOR in Pancreatic Ductal Adenocarcinoma.

Iriana S, Ahmed S, Gong J, Annamalai AA, Tuli R, Hendifar AE.

Front Oncol. 2016 Apr 25;6:99. doi: 10.3389/fonc.2016.00099. eCollection 2016. Review.

42.

Impact of margin status and lymphadenectomy on clinical outcomes in resected pancreatic adenocarcinoma: implications for adjuvant radiotherapy.

Osipov A, Naziri J, Hendifar A, Dhall D, Rutgers JK, Chopra S, Li Q, Tighiouart M, Annamalai A, Nissen NN, Tuli R.

J Gastrointest Oncol. 2016 Apr;7(2):239-47. doi: 10.3978/j.issn.2078-6891.2015.109.

43.

Influence of Body Mass Index and Albumin on Perioperative Morbidity and Clinical Outcomes in Resected Pancreatic Adenocarcinoma.

Hendifar A, Osipov A, Khanuja J, Nissen N, Naziri J, Yang W, Li Q, Tuli R.

PLoS One. 2016 Mar 25;11(3):e0152172. doi: 10.1371/journal.pone.0152172. eCollection 2016.

44.

Meta-analyses of treatment standards for pancreatic cancer.

Gong J, Tuli R, Shinde A, Hendifar AE.

Mol Clin Oncol. 2016 Mar;4(3):315-325. Epub 2015 Dec 18.

45.

Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas.

Zill OA, Greene C, Sebisanovic D, Siew LM, Leng J, Vu M, Hendifar AE, Wang Z, Atreya CE, Kelley RK, Van Loon K, Ko AH, Tempero MA, Bivona TG, Munster PN, Talasaz A, Collisson EA.

Cancer Discov. 2015 Oct;5(10):1040-8. doi: 10.1158/2159-8290.CD-15-0274. Epub 2015 Jun 24.

46.

Review of systemic therapies for locally advanced and metastatic rectal cancer.

Yaffee P, Osipov A, Tan C, Tuli R, Hendifar A.

J Gastrointest Oncol. 2015 Apr;6(2):185-200. doi: 10.3978/j.issn.2078-6891.2014.112. Review.

47.

Dosimetric evaluation of simultaneous integrated boost during stereotactic body radiation therapy for pancreatic cancer.

Yang W, Reznik R, Fraass BA, Nissen N, Hendifar A, Wachsman A, Sandler H, Tuli R.

Med Dosim. 2015 Spring;40(1):47-52. doi: 10.1016/j.meddos.2014.09.001. Epub 2014 Oct 22.

PMID:
25445989
48.

A phase 1B/2 study of aldoxorubicin in patients with soft tissue sarcoma.

Chawla SP, Chua VS, Hendifar AF, Quon DV, Soman N, Sankhala KK, Wieland DS, Levitt DJ.

Cancer. 2015 Feb 15;121(4):570-9. doi: 10.1002/cncr.29081. Epub 2014 Oct 13.

49.

Phase II study of the safety and antitumor activity of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma.

Chawla SP, Cranmer LD, Van Tine BA, Reed DR, Okuno SH, Butrynski JE, Adkins DR, Hendifar AE, Kroll S, Ganjoo KN.

J Clin Oncol. 2014 Oct 10;32(29):3299-306. doi: 10.1200/JCO.2013.54.3660. Epub 2014 Sep 2.

50.

Biomarker-driven EGFR therapy improves outcomes in patients with metastatic colorectal cancer.

Hendifar A, Tan CR, Annamalai A, Tuli R.

Expert Rev Anticancer Ther. 2014 Sep;14(9):1051-61. doi: 10.1586/14737140.2014.922881. Epub 2014 Jun 5. Review.

PMID:
24898788

Supplemental Content

Loading ...
Support Center